Loading
A phase 1/2 trial of UI-102 in advanced solid tumours, run by United Immunity, co., Ltd., now recruiting.
Phase 1/2 Study of UI-102 in Selected Advanced Cancers is a phase 1/2 interventional study registered as NCT07605962 by United Immunity, co., Ltd., with 140 participants planned, started 2026-05-20 and due to reach its primary completion in 2030-03-31. Interventions recorded: UI-102.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/